Introduction
============

Invasive carcinoma of the cervix is the second cause of death in women worldwide, with an estimated 510,000 newly diagnosed cases and 280,000 deaths each year ([@b33] . In developing countries, cervical cancer is often the most common cancer in women. The American Cancer Society (ACS) Cancer Facts and Figures (2007) reported that an estimated 11,150 cases of invasive cervical cancer will be diagnosed in the United States, and an estimated 3,670 women will die from this disease.

Although the incidence of cervical cancer has declined markedly since the introduction of screening tests, the overall mortality rates have not changed in the past 25 years ([@b11]). The American Cancer Society Guideline for the Early Detection of Cervical Cancer was reviewed and updated in 2002; for the first time, those recommendations incorporated options including liquid-based cytology and human papilloma virus (HPV) DNA testing ([@b33] .

The prognosis of advanced cervical cancer is discouraging. Recurrent, persistent or advanced cervical cancer responds poorly to current treatment modalities. Five-year survival rates have been approximately 41%--51% and 8%--17% for patients with regional and distant disease, respectively ([@b35]). Recent addition of chemotherapy to radiation treatment has increased overall survival for patients with regional disease to greater than 60% ([@b37]). Four randomized trials of chemo-radiation demonstrated positive results prompting a National Cancer Institute (NCI) clinical announcement for change in standard of care ([@b14]; [@b22]; [@b31]; [@b28]).

At the present time, there is no effective treatment for metastatic disease and recurrences. Studies of cisplatin chemotherapy in cervical cancer demonstrate response rates of approximately 20%--30% with a median survival of 6--7 months. For recurrent or metastatic disease, chemotherapy is palliative. Complete responses are unusual and generally limited to patients with lung metastasis ([@b4]). The high mortality rate, low response rate to available treatments and short survival mandates investigation into more effective therapies.

Various treatment protocols have been suggested to increase the survival of patients with cervical cancer. These protocols include radiotherapy and chemoradiation for loco-regional disease, and single or combination chemotherapy for widely metastatic or recurrent cancer.

If recurrent disease presents in the central pelvis, then pelvic exenteration by experienced surgeons may yield five-year success rate of 32%--62% in the appropriate patients ([@b10]). Chemotherapy represents the best therapy for recurrent disease not curable by exenterative surgery. Chemotherapy is also the most reasonable option for patients presenting with distant metastases.

Topotecan is an effective chemotherapy agent for treatment of ovarian cancer and small-cell lung cancer. It was approved for use in combination with cisplatin by the US Food and Drug Administration (FDA) in 2006 for treatment of women with stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy ([@b6]). This article will review the role of topotecan in the treatment of advanced (stage IV or widely metastatic) and recurrent cervical cancer.

Pharmacology of topotecan
=========================

Topotecan is a semisynthetic derivative of the pentacyclic alkaloid, camptothecin that is isolated from the Chinese yew tree, *Camptotheca acuminata*. The family of camptothecins includes irinotecan, topotecan, and 9-aminocaptothecin ([@b30]).

Two mechanisms of action have been described for topotecan. The principal mechanism is inhibition of DNA topoisomerase I. During normal DNA replication double stranded DNA separates and topoisomerase I regulates the broken DNA strand. This break is reversible and non-lethal for cell, but camptothecins convert this single stranded break to an irreversible double stranded break ([@b30]). This results in inhibition of RNA transcription and apoptotic cell death. Camptothecins exert their cytotoxic effect predominantly in cell in S phase because of their selective topoisomerase I poisoning effect ([@b15]).

The second, recently discovered mechanism of action of topotecan is inhibition of the hypoxia-inducible factor (HIF). This mechanism is of particular interest in cervical cancer, because tumor tends to be either bulky or present in radiated fields, which often results in tumor hypoxia. HIF is a transcriptional factor, which induces expression of genes encoding proteins enabling cell survival in hypoxic condition. These proteins induce glycolytic enzymes required for anaerobic metabolism and growth factors such as vascular endothelial growth factor that stimulates tumor angiogenesis, as well as erythropoietin that increases the potential of oxygen delivery to the tumor ([@b3]).

Topotecan as a single agent in cervical cancer
==============================================

Topotecan, in preclinical studies, demonstrated significant in vitro activity of solid tumor explants derived from colorectal, breast, ovarian, renal cell, non-small cell lung cancer, and gastrointestinal sources. Notable activity was also demonstrated in vivo in a wide range of animal tumor models.

[@b32] reviewed phase 1 clinical studies with topotecan with as many as 14 different dosing schedules. Complete and partial responses were demonstrated in patients with a wide variety of solid tumors including squamous cell carcinoma. Myelosuppression was the major dose-limiting toxicity across all schedules, and non-hematologic toxicities were generally mild. Based on this information, there was substantial enthusiasm for further evaluating topotecan in a wide range of cancer patients in phase II studies.

[@b23] conducted a Gynecologic Oncology Group (GOG) phase II multicenter study (GOG 76-U) in patients with advanced, recurrent or persistent squamous cell carcinoma of the uterine cervix. Intravenous topotecan was administered at 1.5 mg/m^2^ per day for 5 consecutive days every 4 weeks in patients without prior chemotherapy, aside from chemosensitizing agents used in conjunction with radiotherapy. The median progression-free interval was 2.4 months. The median overall survival was 6.4 months. The overall response rate (complete and partial) was 18.6%. Hematological toxicity was common, with 68% of patients experiencing grade 4 neutropenia and 18% grade 4 thrombocytopenia. Grade 3--4 gastrointestinal and neurologic toxicities were seen in 9% and 5% of patients. However, in patients with prior radiation and borderline renal function, dose reduction of 1.25 mg/m^2^ is recommended. Topotecan administered at this dose and schedule demonstrates moderate activity with substantial hematological toxicity.

[@b5] reported on a multicenter phase II study of patients with previously treated squamous cell carcinoma of cervix (GOG 127-F) who had received one prior chemotherapy regimen . Patients received topotecan 1.5 mg/m^2^ daily for 5 consecutive days on a 21-day cycle. The overall response rate was 12.5%. Progression free interval was 2.1 months and overall survival was 6.6 months. Topotecan had less gastrointestinal toxicity than irinotecan, another derivative of camptothecin with similar overall response rate. The single agent activity of topotecan in cervical carcinoma was also the subject of a report by [@b25] in which 4 of 22 (18%) evaluable patients achieved a partial tumor response.

Most clinical studies have used a 5-day regimen of short intravenous infusions. However, the optimal schedule has not yet been defined. Phase I/II studies have examined 24 hour infusions every 3 weeks versus continuous intravenous for 21 days. These data suggested that topotecan delivered as a continuous intravenous infusion over 21 days as a single- agent therapy does not appear to offer a clinical advantage over conventional 5-day schedules ([@b13]; [@b36]; [@b17]).

Topotecan in combination chemotherapy in cervical cancer: cisplatin and topotecan studies
=========================================================================================

Cisplatin represents the most active single agent in palliative chemotherapy-appropriate cervical cancer and single agent topotecan has demonstrated activity in treatment of cervical cancer. In previous clinical trials of platinum-based therapies in patients with widely metastatic or recurrent cervical cancer, there has often been a tradeoff between response rate and tolerability of treatment regimens, often with no differences in survival for the regimens with more severe toxicity profiles. GOG trial (GOG 110) compared cisplatin monotherapy with two cisplatin-based combination regimens (cisplatin/mitolactol and cisplatin/ifosfamide). Despite higher response rates for the combination therapies, no significant differences in survival were detected; moreover, the cisplatin/ifosfamide group suffered significant neurotoxicity ([@b27]).

Cisplatin monotherapy has also been compared with cisplatin/paclitaxel in patients with recurrent or persistent cervical cancer (GOG Trial 169). The combination therapy was associated with a significantly increased response rate over cisplatin alone (36% vs 19%, p = 0.002) with no difference in median survival (9.7 vs 8.8 months). The cisplatin/paclitaxel group did experience higher incidence of grade 3--4 neutropenia (67% vs 3%) and anemia (27% vs 13%), and grade 1--4 neuropathy (36% vs 21%) ([@b21]).

Topotecan and cisplatin have non-overlapping toxicities; therefore, a phase II trial of topotecan and cisplatin in persistent or recurrent squamous and non-squamous of the cervix was preformed. The tolerability of the cisplatin/topotecan combination has been established in phase I trials ([@b32]; [@b2]; [@b9]). Based on dose-limiting hematological toxicities, the recommended doses for follow up in phase II studies were 0.75 to 1 mg/m^2^/day of topotecan for 5 days and 50 mg/m^2^ of cisplatin on day one.

A phase II trial of cisplatin and a 3-day topotecan regimen was studied with the hypothesis that this would be less bone marrow suppressive especially in previously irradiated patients. The overall response rate in this trial was 28% and median overall survival of 10 months and median progression-free interval of 5 months ([@b12]). Importantly, in this trial responses were seen in tumor in previously irradiated fields.

[@b16] in GOG-0179, a randomized phase III trial, demonstrated a survival advantage for combination chemotherapy over cisplatin alone in advanced cervical cancer. Their regimen included cisplatin 50 mg/m^2^ q 21 days vs cisplatin 50 mg/m^2^ day 1 + topotecan 0.75 mg/m^2^ for 3 days q21 days vs a methotroxate, vinblastin, doxorubicin and cisplatin (MVAC) arm. The MVAC arm was closed due to 4 treatment-related deaths among 63 patients and was not included in the final analysis of the study.

Two hundred ninety-four patients enrolled onto the remaining regimens: 146 to cisplatin and 147 to cisplatin/topotecan. Grade 3 to 4 hematological toxicity was more common with cisplatin/topotecan (see [Table 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}). Patients receiving cisplatin/topotecan had statistically superior outcomes to those receiving Cisplatin alone, with median overall survival (OS) of 9.4 and 6.5 months (p = 0.017), median progression free survival (PFS) of 4.6 and 2.9 months (p = 0.014) and response rate of 27% and 13%, respectively. This trial demonstrated improved PFS and OS when compared with single-agent therapy ([@b16]).

###### 

Hematologic adverse events in patients treated with topotecan + cisplatin or cisplatin alone (derived from data of [@b16])

  Adverse events     Grade   TC 140 patient   C 144 patient
  ------------------ ------- ---------------- ---------------
  Anemia             3       47 (34%)         28 (19%)
                     4       9 (6%)           5 (3%)
  Leukopenia         3       58 (41%)         1 (1%)
                     4       35 (25%)         0 (0%)
  Neutropenia        3       36 (26%)         1 (1%)
                     4       67 (48%)         1 (1%)
  Thrombocytopenia   3       36 (26%)         5 (3%)
                     4       10 (2%)          0 (0%)

**Abbreviations:** C, cisplatin; TC, topotecan + cisplatin.

###### 

Non-hematologic adverse events in patients treated with TC or C alone (derived from data of [@b16])

  Adverse events         TC    C
  ---------------------- ----- -----
  Gastrointestinal       45%   28%
  Pain                   22%   16%
  Metabolic-Laboratory   14%   10%
  Hepatic                5%    1%
  Dermatologic           48%   20%

**Abbreviations:** C, cisplatin; TC, topotecan + cisplatin.

Topotecan plus cisplatin combination regimen was approved by the Food and Drug Administration (FDA) in 2006, for use in recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. [@b6] reviewed the database supporting this approval.

The GOG instituted a multi-arm trial of cisplatin in combination with vinorelbine, gemcitabine, paclitaxel or Topotecan (GOG-204). Earlier this year, the GOG interim analysis closed the study when data "indicated that all the experimental arms... were unlikely to demonstrate improved survival over control (cisplatin and paclitaxel)". Unfortunately, the toxicity data from the four arms will not be revealed until the survival data mature. Thus it is difficult to conclude if one arm is superior on the basis of toxicity given presumably similar survival rates. Based upon phase III data, Topotecan/cisplatin carries greater hematological toxicity but less risk of neuropathic pain. A guiding principle for palliative chemotherapy is minimization of symptoms and side-effects that worsens a patient's quality of life. In our institution, we favor the FDA approved combination until data from GOG-204 are published.

Other combinations of topotecan
===============================

A combination of topotecan and paclitaxel for treatment of persistent, recurrent or metastatic cervical cancer was investigated in a phase II study of 15 patients. The treatment protocol consisted of 175 mg/m^2^ paclitaxel on day1 and 1 mg/m^2^ topotecan on days 1--5 of a 25-day cycle with granulocyte colony stimulating factor (GCSF) support and the standard pretreatment regimen for paclitaxel. Overall response was 54% and progression-free survival 3.7 months with a median overall survival of 8.6 months. Grade 3/4 toxicities included anemia (47%), leukopenia (27%), neurotoxicity (13%), thrombocytopenia (13%), and diarrhea (13%) ([@b35]).

The several combination chemotherapeutic protocols have not shown improved response, or had similar response with more severe toxicities in most patients than those treated by Cisplatin and topotecan combination (see [Table 3](#tbl3){ref-type="table"}).

###### 

Combination regimens in treatment of persistent or recurrent cervical cancer

  Author   Agent                           Dose                                     Response Rate %   Toxicity
  -------- ------------------------------- ---------------------------------------- ----------------- -----------------------------------
  [@b7]    C+gemcitabine                   30 mg/m^2^+800 mg/m^2^/d 1,8 Q 28 d      22                Hematologic
  [@b19]   C+pentoxifylline                75 mg/m^2^+1600 mg PO 9 d Q8H q21d       10                N/V 32%, hematologic 23%
  [@b38]   C+ifosfamide+paclitaxel (TIP)   75 mg/m^2^+5 g/m^2^+175 mg/m^2^          52                Myelotoxicity 91%
  [@b8]    (TIP)                           50 mg/m^2^+1500 mg/m^2^+135 mg/m^2^      46.7              Neutropenia 13%- neurotoxicity 5%
  [@b29]   C+decitabine                    40 mg/m^2^+50 mg/m^2^ q21d               38.1              Neutropenia 68%
  [@b18]   C+Tirapazamine                  75 mg/m^2^+330 mg/m^2^                   27.8              Anemia, fatigue, N/V
  [@b34]   C+ifosfamide+mitomycin          50 mg/m^2^+3 g/m^2^ q21d                 34                Leukopenia 59%
  [@b24]   C+irinotecan                    25 mg/m^2^+65 mg/m^2^ q21d               16                Myelosuppression+gastrointestinal
  [@b26]   Irinotecan+nedaplatin           50 mg/m^2^/d 1,8,15+60 mg/m^2^/d 1q4wk   40                Leukopenia 40%, neutropenia 38%

**Abbreviations:** C, cisplatin; TIP, cisplatin + ifosfamide + paclitaxel; N/V, nausea/vomiting

Quality of life (QOL) during topotecan treatment
================================================

Several studies have investigated the QOL in patients with advanced cervical cancer with treatments. Patient-reported QOL measures are an important considerations when using chemotherapy with non-curative intent. [@b20] examined QOL data in conjunction with the GOG randomized phase III trial of cisplatin with or without topotecan. They demonstrated no statistically significant differences in QOL up to 9 months after randomization. QOL was assessed using Functional Assessment of Cancer Therapy-General (FACT-G), Cervix subscale (Cx subscle), FACT/GOG-Neurotoxicity subscale (NTX subscale), Brief Pain Inventory(BPI), and UNISCALE (UNI). They concluded that despite increased hematological toxicity, cisplatin/topotecan did not significantly reduce the QOL when compared with cisplatin alone (p = 0.0016).

Toptecan and radiation
======================

Topotecan has also been examined as a radiosensitizing agent due to its ability to both sabotage repair of sublethal cell injury and to prevent HIF-regulated hypoxic cell survival. [@b9] studied the maximal tolerance dose (MTD) of topotecan with external beam radiotherapy in advanced cervical cancer. They concluded that topotecan can be safely administered at a dose of 1 mg/m^2^ daily for 5 days on days 1--5 and 22--26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and grade II leukopenia in two cases were seen at this dose level. Dose limiting toxicity was not reached.

[@b2] published a phase I study using topotecan during radiation implant after completion of external-beam therapy. He found the maximum tolerated dose of 0.5 mg/m^2^. The data differed by dose and pretreatment with external beam therapy.

Future directions
=================

Several phase II studies have demonstrated topotecan to be an active agent in cervical cancer. ([Table 4](#tbl4){ref-type="table"}) In an effort to ameliorate toxicity noted with 3- to 5-day dosing regimens of topotecan, investigators are currently recruiting patients in a phase I study for efficacy of weekly topotecan with cisplatin in advanced stage or recurrent cervical cancer. Topotecan will be given weekly at escalating dose levels starting at 2.0 mg/m^2^ with standard cisplatin at 50 mg/m^2^ every 21 days (available at [www.clinicaltials.gov](www.clinicaltials.gov) identifier NCT00322920 ). Also, a phase II evaluation of weekly topotecan is currently underway in patients with persistent or recurrent carcinoma of the cervix (available at <http://ycctrials.med.yale.edu/listprotocolsbydisease.asp>).

###### 

Topotecan in phase II studies for treatment of recurrent cervical carcinoma

  Study    Treatment history                   Treatment                                               Number of patients   PFS   RR    OS
  -------- ----------------------------------- ------------------------------------------------------- -------------------- ----- ----- ------
  [@b25]   76% prior chemotherapy              Topotecan 1.2 mg/m^2^, 5 days                           22                   NR    18%   NR
  [@b1]    Platinum prior based chemotherapy   Topotecan 1 mg/m^2^/d on days 1--5 of a 21-day cycwle   12                   NR    17%   NR
  [@b23]   No chemotherapy                     Topotecan 1.5 mg/m^2^                                   40                   2.1   13%   6.4
  [@b5]    88% prior chemotherapy              Topotecan 1.5 mg/m^2^                                   40                   2.1   13%   6.6
  [@b12]   No chemotherapy                     Topotecan 0.75 mg/m^2^ + cisplatin 50 mg/m^2^           32                   5     28%   10
  [@b35]   Prior radiotherapy                  Topotecan 1 mg/m^2^ + paclitaxel 175 mg/m^2^            15                   3.7   54%   8.62

**Abbreviations:** NR, not reported; OS, overall survival; PFS, progression-free survival; RR, response rate.

Weekly topotecan in combination with pemetrexed is in a phase I trial in patients with advanced malignancies (available at [www.clinicaltials.gov](www.clinicaltials.gov) Identifier NCT00315861).

Lastly, the combination of paclitaxel together with topotecan and cisplatin in treating patients with advanced, persistent, or recurrent cervical cancer is being evaluated in a phase II trial (available at [www.clinicaltrials.gov](www.clinicaltrials.gov) ID numbers CDR000456248; GOG-0076EE).

In an effort to further improve radiosensitization, phase II trials is currently underway studying topotecan and cisplatin with radiation in cervical carcinoma (available at [www.clinicaltrials.gov](www.clinicaltrials.gov) Identifier NCT00257816; NCT003220983 and NCT000287911). It is expected that synergy between the drugs due to downregulation of HIF by Topotecan in poorly perfused tumors.

Conclusion
==========

Improvements in cervical cancer screening have led to a decline in the incidence of cervical cancer, but this diseaese is still a leading cause of cancer related mortality worldwide. Advances in the treatment of cervical cancer have led to the use of chemoradiation in locally advanced disease, but few treatment options remain for women with advanced, recurrent, or persistent disease. Topotecan and cisplatin combination approved by FDA have produced higher survival and progression free survival rates in the management of these patients. Data from GOG 204 will need to be evaluated to determine the effect of survival with combination therapy. Topotecan is being investigated in its role as a chemosensitizer in patients receiving radiotherapy. Ongoing studies to find better combination and dosing regimen with less toxicity and more efficient therapy are needed to continue to improve the QOL and survival of patients with persistent or recurrent cervical cancer.
